Live at the 50th ICAAC

MeetFaculty_Ad

Login

Username:

Password:


New to ViralEd?
Enter your email address below to register:

Lost Password? | Register now!

Register now and gain access to forums and other interactive content geared specifically to medical professionals!

HIV News

Follow us on Twitter-small FB_small logo
Receive brief, clinically relevant news updates daily. 

For the latest Hepatitis News, please scroll down.    

  • 8/31 -  OIs and CA decline steeply after ART initiation; >1/3 of HOPS cohort who developed OI did so at CD4 counts at ≥200, threshold for OI prophy should be considered (HIV&Hepatitis)
  • 8/31 - Male sex, family hx, smoking, ab lipids, and HTN predict atherosclerosis and CV events; TDF may have protective effect; D-dimer, VCAM-1, TIMP-1 linked to CVD; no link btw CVD and lower CD4 cell count (HIV&Hepatitis
  • 8/31 - 31% of HIV+ people at risk for CVD may benefit from taking ASA QD; consider ASA as primary prevention rx (HIV&Hepatitis)
  • 8/31 - PCP prophy may be d/c'd if VL <50 when CD4 is btw 101-200; incidence of PCP in this population was low irrespective of prophy use (HIV&Hepatitis)
  • 8/31 - CNS serves as reservior for HIV even in VL <50; inflammation may persist despite ART; EFV suppressed HIV in brain faster than PI/r's; high dose IV IgG reduced latently infected CD4 cells in brain (HIV&Hepatitis
  • 8/31 - A protein on rhesus macaques TRIM4a responsible for inhibiting HIV infection in species; ID may point way to future therapies using genetic engineering (HIV&Hepatitis
  • 8/27 - Excessive immune activation, causing inflammation and premature exhaustion of immune cells.
  • 8/27 - ART may reverse some of these changes, preventing non-AIDS conditions (HIV&Hepatitis
  • 8/27 - PIE12-trimer, cell entry inhibitor, may be a candidate for a vaginal microbicide. It binds to the gp41 pocket conferring a higher barrier of resistance (HIV&Hepatitis
  • 8/25 - HIV testing offered at home to household members of HIV-infected adults initiating ART associated with a 10-fold increased likelihood of testing. (aidsmap
  • 8/25 - Breastfeeding is associated w/ significantly lower malaria incidence in HIV-exposed children; but protection fades w/ age. Recommend breastfeeding and co-trimoxazole prophy. (aidsmap)
  • 8/24 - Precancerous anal cell changes in men common, regardless of VL and restored CD4 cells; invasive cervical cancer in women associated with lower CD4 cells (HIV&Hepatitis)  
  • 8/24 - Sexual risk behaviour does not increase in IDUs who start HIV rx (aidsmap)
  • 8/24 - Universal HIV testing followed by immediate initiation of ART for those infected could reduce transmission by 15-27%. Testing and linkage to care should part of a multi-pronged HIV prevention approach (HIV&Hepatitis
  • 8/24 - IDUs, heavy alcohol users, individuals w/ mental health problems, people of color, women and transgender people were less likely to acheive undetectable VL and their all-cause mortality increased over time despite ART (HIV&Hepatitis)
  • 8/24 - Decitabine and gemcitabine, anti-cancer rx, together reduced HIV infectivity by 75% in mice. Increased mutation frequency lead to "lethal mutagenesis" (HIV&Hepatitis
  • Integrase promoter and SQV led to apoptosis of infected HIV cells. Non-infected cells not affected (HIV&Hepatitis
  • 8/24 - Heroin use, AIDS, predict reduced bone mineral density in older men with HIV (aidsmap
  • 8/20 - Rx-failures more likely w/ ≥1 drug-resistance mutation; PIs may be advisable if pre-rx genotypes not available (HIV&Hepatitis
  • 8/20 - ETV has fewer neuropsychic side effects than EFV, switching may improve sx (HIV&Hepatitis
  • 8/20 - Less than 1% of people w/ HIV for 15-y did not experience disease progression in the absence of ART. All but 10% required ART and only 0.25% were considered Controllers (HIV&Hepatitis
  • 8/20 - DHHS Pediatric ART Guidelines released: new rating system, drug characteristic/info appendix, AE info in table format, dx of infants, when/what to start, and adherence (AIDSinfo
  • 8/20 - Need for prevention campaigns reaching beyond gay community: MSM's 9% report are HIV+, 18% HSV-2+, < 1/2 reported themselves as gay (HIV&Hepatitis)

Hepatitis News

Follow us on Twitter-small FB_small logo  

For the latest HIV news, please scroll up. 

  • 8/31 - Spontaneous clearing of HCV w/o rx has low risk (10% over 5 yrs) of death; CHC is at elevated risk of overall and liver-related mortality, including HCC (HIV&Hepatitis)
  • 8/31 - PegIFN + RBV has high SVR in HCV+ children; 60% with HCV G1 & G4, and 90% with HCV G2 and 3 achieved cure (HIV&Hepatitis
  • 8/27 - IL28B gene patter may influence susceptibility to HCV genotypes: CC IL28B significantly more common among non-1 HCV genotypes (HIV&Hepatitis
  • 8/27 - The fittest HCV viruses had mutations in one region of the surface protein the virus uses to infect cells in new liver transplantation. Blocking this region may provide a new way to prevent reinfection (HIV&Hepatitis
  • 8/27 - ADF plus LAM is better "rescue therapy" for LAM-resistant HBV, rather than switching to ETV (HIV&Hepatitis
  • 8/24 - TDF and ETV for the rx of HBV are the most potent oral agents for HBeAg+ pts; TDF most effective for HB3Ag- pts (HIV&Hepatitis)
  • 8/24 - TMC435 demonstrates potent antiviral activites in PILLAR study maintaining HCV SVR through 12-weeks (HIV&Hepatitis
  • 8/24 - Neurocognitive effects previously reported in HIV/HCV may begin to happen soon after HCV acquisition (HIV&Hepatitis) 
  • 8/20 - Silymarin, milk thistle extract, has an inhibitory effect on HCV, but may have cell entry blocking mechanism (HIV&Hepatitis
  • 8/20 - Acute HCV in HIV+ men: HIV probably plays a critical role mediated either through behavioral and/or biological factors (HIV&Hepatitis)
  • 8/19 - Genetic variation near the IL28B gene and aa substitution of the core region predict SVR to TPV/pegIFN/r (Hepatology

 

ViralEd News

View ViralEd News Archives


Featured Programs

Share this page:

                             


Current Programs
ViralEd, medical, medicine, HIV, AIDS, antiretrovirals, medical education, CME, slide set, conference report, CROI, ICAAC, AASLD,  EACS, IAS, EASL, hepatitis, healthcare, scientific communication, virology, virus, medication, HIV, slide set, conference report, cancer, genomics, genes, genetics,  scientific communication, virology, virus
ViralEd, medical, medicine, HIV, AIDS, antiretrovirals, medical education, CME, slide set, conference report, CROI, ICAAC, AASLD,  EACS, IAS, EASL, hepatitis, healthcare, scientific communication, virology, virus, medication, HIV, slide set, conference report, cancer, genomics, genes, genetics,  scientific communication, virology, virus
ViralEd, medical, medicine, HIV, AIDS, antiretrovirals, medical education, CME, slide set, conference report, CROI, ICAAC, AASLD,  EACS, IAS, EASL, hepatitis, healthcare, scientific communication, virology, virus, medication, HIV, slide set, conference report, cancer, genomics, genes, genetics,  scientific communication, virology, virus
  • Antiretroviral Treatment Strategies in the Correctional Setting
    October 2010 Web-based programs with live Q&A
    Featuring Course Director John Bartlett, MD, Johns Hopkins; David Wohl, MD, University of North Carolina - Chapel Hill; and Frederick Altice, MD, Yale University